 |
|
Atypical Depression, Panic Attacks, and Response to Imipramine and PhenelzineA Replication
Frederic M. Quitkin, MD;
Patrick J. McGrath, MD;
Jonathan W. Stewart, MD;
Wilma Harrison, MD;
Elaine Tricamo, RN;
Steven G. Wager, MD;
Katja Ocepek-Welikson, MPhil;
Edward Nunes, MD;
Judith G. Rabkin, PhD;
Donald F. Klein, MD
Arch Gen Psychiatry. 1990;47(10):935-941.
Abstract
• In an initial study with 120 patients with reactive mood and associated atypical symptoms, phenelzine sulfate was superior to imipramine hydrochloride and placebo. Since their response to phenelzine appears to be unique, this suggests that atypical depression may be a distinct subgroup of unipolar depressive illness. Unexpectedly, the benefit of antidepressants was limited to patients who also had spontaneous panic attacks. To help establish the validity of this syndrome, a new sample of 90 atypical depressives was studied. The clinical and demographic characteristics of the original and replication sample were virtually identical at baseline. In addition, the treatment response with either placebo, imipramine, or phenelzine was also indistinguishable in the two patient groups. The outcome in the replication study supports the hypothesis that this may be a distinct unipolar depressive subgroup. In the replication sample, a history of panic attacks did not appear to be a relevant predictor. We discuss the explanations for this discrepancy in the two patient samples.
Author Affiliations
From the Department of Psychiatry, Columbia University, New York, NY, and the New York (NY) State Psychiatric Institute.
Footnotes
Accepted for publication December 7, 1989.
Reprint requests to New York State Psychiatric Institute, 722 W 168th St, Box 12, New York, NY 10032 (Dr Quitkin).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
MAO inhibitors: Risks, benefits, and lore
WIMBISCUS et al.
Cleveland Clinic Journal of Medicine 2010;77:859-882.
ABSTRACT
| FULL TEXT
Treatment-Resistant Depression: Critique of Current Approaches
Wijeratne and Sachdev
Aust N Z J Psychiatry 2008;42:751-762.
ABSTRACT
| FULL TEXT
Australian and New Zealand Clinical Practice Guidelines for the Treatment of Depression
Royal Australian And New Zealand College Of Psychi
Aust N Z J Psychiatry 2004;38:389-407.
ABSTRACT
| FULL TEXT
Depression With Atypical Features in the National Comorbidity Survey: Classification, Description, and Consequences
Matza et al.
Arch Gen Psychiatry 2003;60:817-826.
ABSTRACT
| FULL TEXT
Treatment of Atypical Depression With Cognitive Therapy or Phenelzine: A Double-blind, Placebo-Controlled Trial
Jarrett et al.
Arch Gen Psychiatry 1999;56:431-437.
ABSTRACT
| FULL TEXT
Treating Major Depression in Primary Care Practice: An Update of the Agency for Health Care Policy and Research Practice Guidelines
Schulberg et al.
Arch Gen Psychiatry 1998;55:1121-1127.
ABSTRACT
| FULL TEXT
The Identification and Validation of Distinct Depressive Syndromes in a Population-Based Sample of Female Twins
Quitkin et al.
Arch Gen Psychiatry 1997;54:970-972.
ABSTRACT
Chronological Milestones to Guide Drug Change: When Should Clinicians Switch Antidepressants?
Quitkin et al.
Arch Gen Psychiatry 1996;53:785-792.
ABSTRACT
Response to Phenelzine and Imipramine in Placebo Nonresponders With Atypical Depression: A New Application of the Crossover Design
Quitkin et al.
Arch Gen Psychiatry 1991;48:319-323.
ABSTRACT
|
